@yusufhameed The problem with firing Sandy now is that $SGMO would need to find a replacement -- and that's a job no one wants.
$SGMO is the clown car inside the burning dumpster inside the runaway train careening off the tracks of biotech.
$SGMO And a $25M distressed financing. https://t.co/gqA4ff33Im
$SGMO fired its principal financial officer https://t.co/lAvBbhJYaH
Not including $SGMO CEO Sandy Macrae on my '25 Worst CEO list was an oversight on my part. He belongs on the list. This filing is just stupid.
@Franca_ole No, it doesn't. The FDA won't review $SGMO 's BLA until the rolling submission is complete. Rolling BLA submissions aren't new or special. It signals nothing.
@staycaffeinated @pemulisking One might argue $SGMO is irresponsible to press ahead knowing it cannot pay for this program. Maybe the FDA should include assurance of financial solvency into its filing guidance.
$SGMO still no partner for its Fabry gene therapy. Sangamo moving forward with FDA submission despite having no money.
$SGMO no deals and just $29M in cash. Sad trombone…
Are real people behind the flood of delusional $SGMO posts, or is this just some weird bot campaign?
Sangamo’s $SGMO Fabry therapy partner search looks futile Plus: Geoff Porges returns to biopharma as a Wall Street banker https://t.co/K6uWkVIBjo
This week's Biotech Scorecard newsletter: - $SGMO 's Fabry therapy partner search looks futile - Geoff Porges is back on Wall Street, taking a banking role at Lazard - Don't get rid of FDA adcomms, make them better. I have a few ideas, including: Eliminate the public hearing where patients and advocates basically intimidate experts into voting yes, even when the data say otherwise. - Comments from Peter Marks and $AMGN at a recent conference. Link to web version of the newsletter below.
@yusufhameed @Jasonmmast @DrMakaryFDA @VPrasadMDMPH Good science, if that's even true with $SGMO, is most definitely not enough.
$SGMO CFO resigned. Tell me again about the imminent Fabry gene therapy deal?
